Methods of improving autonomic imbalance or sympathetic impairment by regulating the stellate ganglion
Methods of improving ARDS by regulating a stellate ganglion is provided herein. Methods of improving a hypercoagulation state are also provided by regulating the sympathetic nervous system.
1 . A method of improving acute respiratory distress syndrome (ARDS) in a human patient suffering therefrom comprising:
delivering a therapeutically effective dose of an anesthetic to the human patient's stellate ganglion (SG) to regulate function of the SG to improve the human patient's ARDS wherein the anesthetic is selected from lidocaine, bupivacaine or combinations thereof.
2 . The method of claim 1 , wherein improving the patient's ARDS comprises improving autonomic nervous system (ANS) imbalance and/or sympathetic impairment in the patient.
3 . The method of claim 1 , wherein improving the patient's ARDS comprises improving the patient's, cardiac function, cardiopulmonary function, neural function, ocular function, nasal function, liver function, blood vessel function, heart function, pulmonary function, immune function, endocrine function, kidney function, gastrointestinal function, or combinations thereof.
4 . The method of claim 1 , wherein improving the patient's ARDS comprises improving the cardio-pulmonary sympathetic hyperactivity, sympathetic sensitization, sympathetic dysregulation, or combinations thereof in the patient.
5 . The method of claim 1 , wherein the patient suffers from COVID-19 induced ARDS and improving the patient's ARDS comprises improving the patient's COVID-19 induced ARDS.
6 . The method of claim 1 , wherein improving the patient's ARDS comprise improving the patient's lung function.
7 . The method of claim 1 , wherein improving the patient's ARDS comprises improving the patient's heart failure, reducing the patient's cardiac arrythmias, improving the patient's cardiomyopathy, improving the patient's heart contractility, or combinations thereof.
8 . The method of claim 1 , wherein improving the patient's ARDS comprises reducing the utilization of extra-corporeal membrane oxygenation (ECMO), improving ventilator settings, reducing cardiopulmonary support interventions, or combinations thereof.
9 . The method of claim 1 , wherein improving the patient's ARDS comprises improving the patient's sympathetic tone, sympathetic activity, sympathetic/parasympathetic balance, sympathetic irritability, sympathetic sensitization, sympathetic regulation, or combinations thereof.
10 . The method of claim 9 , wherein improving the patient's sympathetic tone facilitates function and homeostasis and improves the patient's disease or function.
11 . The method of claim 1 , wherein improving the patient's ARDS comprises reducing blood clots and hypercoagulation in the patient's cardiopulmonary and peripheral vascular system.
12 . The method of claim 1 , wherein improving the patient's ARDS comprises improving the patient's vascular status.
13 . The method of claim 12 , wherein improving the patient's ARDS comprises reducing constriction of blood vessels leading to and from the patient's lungs.
14 . The method of claim 1 , wherein improving the patient's ARDS comprises acutely improving the patient's ARDS, improving chronic effects of ARDS, and combinations thereof.
15 . A method of improving ARDS in a patient suffering therefrom comprising the steps of:
obtaining a measurement of a physiological parameter of the patient indicative of ANS imbalance and/or sympathetic impairment; and
delivering a therapeutically effective dose of an anesthetic to the patient's stellate ganglion (SG) to regulate and optimize the function of the SG based on the measurement of the physiological parameter of the patient to improve the patient's ARDS wherein the anesthetic is selected from lidocaine, bupivacaine or combinations thereof.
16 . A method of improving ARDS in a patient suffering therefrom comprising:
obtaining a measurement of a baseline value of a physiological parameter of the patient indicative of ANS imbalance, sympathetic sensitization, sympathetic dysregulation and/or sympathetic impairment;
delivering a therapeutically effective dose of an anesthetic to the patient's stellate ganglion (SG) to regulate function of the SG;
obtaining a subsequent measurement of a resultant value of the physiological parameter of the patient during or after delivering the therapeutically effective dose of the anesthetic to the SG;
obtaining a comparison of the resultant value to the baseline value to determine if the patient's ARDS has improved; and
applying or adjusting delivery of the therapeutically effective dose of the anesthetic to the SG based upon a determination that the patient's ARDS has not improved to improve the patient's ARDS wherein the anesthetic is selected from lidocaine, bupivacaine or combinations thereof.
17 . The method of claim 1 , wherein the anesthetic is lidocaine.
18 . The method of claim 15 , wherein the anesthetic is lidocaine.
19 . The method of claim 16 , wherein the anesthetic is lidocaine.